Apremilast as a treatment for psoriasis

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 12, 2012, Pages 1761-1770

  Shutty, Brandon ^a   West, Cameron ^a   Pellerin, Megan ^a   Feldman, Steven ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Cytokines; PDE 4; Phosphodiesterase type 4; Psoriasis; TNF alpha

Indexed keywords

ADALIMUMAB; APREMILAST; CORTICOSTEROID; CYCLOSPORIN; DRUG METABOLITE; ETANERCEPT; ETRETIN; INFLIXIMAB; JANUS KINASE INHIBITOR; METHOTREXATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; RETINOID; ROFLUMILAST; ROLIPRAM; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D DERIVATIVE;

ACNE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BACKACHE; BLOOD TOXICITY; CHEMICAL STRUCTURE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOPIGMENTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LIVER TOXICITY; LOCAL SKIN REACTION; LUNG TOXICITY; MAXIMUM PLASMA CONCENTRATION; NATURAL KILLER CELL; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGITIS; PHOTOTHERAPY; PRACTICE GUIDELINE; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ATROPHY; STRIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ANIMALS; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PSORIASIS; THALIDOMIDE;

EID: 84864036776     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.699959     Document Type: Review

References (64)

1. Patel RV, Lebwohl M. In the clinic. Psoriasis. Ann Intern Med 2011;155:ITC2-1-ITC2-15
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
3. Kurd SK, Gelfand JM. The prevalence of previously diagnosed psoriasis in US adults: Results from NHANES 2003 -2004. J Am Acad Dermatol 2009;60(2):218-224
4. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: A review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011;12:2041-2054
5. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: A review. Australas J Dermatol 2004;45:155-159
6. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: Physical severity, quality of life and stigmatization. Phyiol Behav 2000;70:567-571
7. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2011; Epub ahead of print
8. Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: A combined analysis. Am J Epidemiol 2012. [Epub ahead of print]
9. Green L. An overview and update of psoriasis. Nurs Stand 2011;25:47-55
10. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care of the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-850
11. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65(1):137-174
12. Murphy G, Reich K. In touch with psoriasis: Topical treatments and current guidelines. J Eur Acad Dermatol Venereol 2011;25(Suppl 4):3-8
13. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012;146(1):95-102
14. Sukarovska BG, Lipozencic J, Vrzogic P. Topical corticosteroids and corticosteroid sparing therapy in psoriasis management. Acta Med Croatica 2007;61(4):375-381
15. Reich K, Bewley A. What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol 2011;25(Suppl 4):15-20
16. Del Rosso J, Friedlander SF. Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005;53(1, Suppl 1):S50-8
17. Kurian A, Barankin B. Current effective topical therapies in the management of psoriasis. Skin Therapy Lett 2011;16(1):4-7
18. Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997;37(2,Pt3):S18-24
19. Scheinfled N. The use of topical tacrolimus and pimecrolimus to treat psoriasis: A review. Dermatol Online J 2004;10(1):3
20. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: Mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002;27(7):555-561
21. Kemeny L, Ruzicka T, Braun-Falco O. Dithranol: A review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 1990;3(1):1-20
22. Horn EJ, Domm S, Katz HI, et al. Topical corticosteroids in psoriasis: Strategies for improving safety. J Eur Acad Dermatol Venereol 2010;24(2):119-124
23. Ryan C, Abramson A, Patel M, Menter A. Current investigational drugs in psoriasis. Expert Opin Investig Drugs 2012;21(4):473-487
24. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: Results of a pilot study. J Am Acad Dermatol 2003;49(4):651-654
25. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002;288(22):2868-79; Review. Erratum in: jama. 2003;289(24):3242
26. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003;149(3):582-589
27. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56(2):211-216
28. Richards HL, Fortune DG, O'sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41(4):581-583
29. Rapp SR, Exum ML, Reboussin DM, et al. The Physical, psychological and social impact of psoriasis. J Health Psychol 1997;2:525-537
30. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-485
31. Braddock M, Murray C. 10th anniversary inflammation and immune diseases drug discovery and development summit. Expert Opin Investig Drugs 2006;15:721-727
32. Gottlieb AB, Strober B, Krueger et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24:1529-1538
33. Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism, and mass balance of [14C] apremilast following oral administration. Xenobiotica 2011;41:1063-1075
34. Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-{2-[1-(3-Ethoxy-4- methoxy-phenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009;52:1522-1524
35. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-855
36. Houslay MD, Schafer P, Zhang KY. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10(22):1503-1519
37. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signaling cross-talk, desensitization and compartmentalization. Biochem J 2003;370(Pt 1):1-18
38. Houslay MD. Underpinning compartmentalised camp signaling through targeted camp breakdown. Trends Biochem Sci 2010;35(2):91-100
39. Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007;10(7):950-966
40. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159(4):842-855
41. Gloerich M, Bos JL. Epac: Defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 2010;50:355-375
42. Scheibner KA, Boodoo S, Collins S, et al. The adensosine a2a receptor inhibits matrix-induced inflammation in a novel fashion. Am J Respir Cell Mol Biol 2009;40(3):251-259
43. Xing J, Birukova AA. ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha. Microvasc Res 2010;79(1):56-62
44. Xu XJ, Reichner JS, Mastrofrancesco B, et al. Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. J Immunol 2008;180(4):2125-2131
45. Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2011;published online 17 October 2011; doi:10.1001/archdermatol.2011.301
46. Gordan JN, Prothero JD, Thornton CA, et al. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis 2009;3:175-182
47. Khobzaoui M, Gutke HJ, Burnet M. CC-10004. Curr Opin Investig Drugs 2005;6:518-525
48. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumor necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010;12:R107
49. Paramio JM, Casanova ML, Segrelles C, et al. Modulation of cell proliferation by cytokeratins K10 and K16. Mol Cell Biol 1999;19(4):3086-3094
50. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-285
51. Papp K, Zeldis J, Rohane P, Thaci D. A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis. J Am Acad Dermatol 2008;58(2, Suppl 2):abstract P2614
52. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2008;30:313-331
53. Papp K, Hu A, Day R. Oral apremilast is active in the treatment of moderate to severe plaque psoriasis: Results from a phase 2b, randomized, controlled study (PSOR-005) [abstract 273]. J Invest Dermatol 2011;131:S46
54. Apremilast. Clinicaltrials.gov: A service of the U.S. National Institutes of Health. Available from: Http://clinicaltrials.gov/ct2/results?flds= Xf&flds=a&flds=b&term=apremilast&show-flds=Y [Accessed 23 December 2011]
55. Pinner NA, Hamilton LA, Hughes A. Roflumilast: A phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther 2012;34(1):56-66
56. Kosari P, Feldman SR. Case report: Fluocinonide-induced perioral dermatitis in a patient with psoriasis. Dermatol Online J 2009;15(3):15
57. Tempark T, Phatarakijnirund V, Chatproedprai S, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: Case report and review literature. Endocrine 2010;38(8):328-334
58. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on biologics. J Am Acad Dermatol 2008;58(5):851-864
59. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-850
60. Montaudie H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: A systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):12-18
61. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporine in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):19-27
62. Houslay MD, Schafer P, Zhang KY. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10(22):1503-1519
63. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-175
64. Daliresp [package insert]. Forrest Pharmaceuticals; St. Louis, Mo: 2010